Source: Circulation. Unidade: FMRP
Subjects: ULTRASSONOGRAFIA, DIABETES MELLITUS, ARTERIOSCLEROSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GERSTEIN, Hertzel C. et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation, v. 121, n. 10, p. 1176-1187, 2010Tradução . . Acesso em: 10 nov. 2024.APA
Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W., García-García, H. M., Es, G. -A. van, et al. (2010). Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation, 121( 10), 1176-1187.NLM
Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, Es G-A van, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW, Marin Neto JA. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. 2010 ; 121( 10): 1176-1187.[citado 2024 nov. 10 ]Vancouver
Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, Es G-A van, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW, Marin Neto JA. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. 2010 ; 121( 10): 1176-1187.[citado 2024 nov. 10 ]
